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Background-—Vascular complications and abnormal platelet function contribute to morbidity and mortality in diabetes mellitus. We
hypothesized that the Rho-related GTPase protein, Rac1, can influence both endothelial and platelet function and might represent a
potential novel therapeutic target in diabetes mellitus.
Methods and Results-—We used both in vitro and ex vivo approaches to test the effects of pharmacological inhibition of Rac1
during hyperglycemic condition. We evaluated the effect of NSC23766, a pharmacological inhibitor of Rac1, on vascular function in
diabetic mice and platelet aggregation in diabetic subjects. We demonstrated that the administration of NSC23766 protects from
hyperglycemia-induced endothelial dysfunction, restoring NO levels, and reduces oxidative stress generated by nicotinamide
adenine dinucleotide phosphate oxidase. Mechanistically, we identified Rho-associated coiled-coil serine/threonine kinase-1 as a
downstream target of Rac1. Moreover, we reported that during hyperglycemic conditions, human platelets showed hyperactivation
of Rac1 and impaired NO release, which were both partially restored after NSC23766 treatment. Finally, we characterized the
antiplatelet effect of NSC23766 during hyperglycemic conditions, demonstrating the additional role of Rac1 inhibition in reducing
platelet aggregation in diabetic patients treated with common antiplatelet drugs.
Conclusions-—Our data suggest that the pharmacological inhibition of Rac1 could represent a novel therapeutic strategy to reduce
endothelial dysfunction and platelet hyperaggregation in diabetes mellitus. ( J Am Heart Assoc. 2018;7:e007322. DOI: 10.1161/
JAHA.117.007322.)
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M acrovascular and microvascular complicationscontribute to morbidity and mortality in diabetes
mellitus.1–3 Endothelial dysfunction and abnormal platelet
function represent the main determinants of the vascular
accidents in diabetic patients, contributing to high incidence
of thrombotic events.4 Chronic hyperglycemia observed in
type 2 diabetes mellitus induces platelet activation and
increases reactive oxygen species (ROS) production in
endothelium, playing an important role in the development
of vascular damage.5,6
The small GTPase Rac1 is essential for the correct
assembly of nicotinamide adenine dinucleotide phosphate
oxidase (Nox) subunits.7 Several pathways converge in the
activation of Rac1, and some evidence suggests a role in
different cellular mechanisms, such as cell adhesion, chemo-
taxis, and vascular permeability.7 In addition to its role in ROS
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generation in endothelium, Rac1 represents a key orchestra-
tor of platelet actin cytoskeleton, modulating, in turn, platelet
aggregation.8 The role of Rac1 in hyperglycemia-induced
platelet hyperaggregation is still poorly understood.
Antiplatelet drugs, such as aspirin, are prescribed to
diabetic patients for prevention of ischemic cardiovascular
diseases; however, many patients exhibit “aspirin resistance”
with a high rate of cardiovascular events.9–11 Furthermore,
despite optimal antiplatelet therapy, many patients exhibit
high residual platelet reactivity, which has been associated
with higher risk of cardiovascular events as well.12 Therefore,
even a small variation in platelet activity might precipitate
thrombotic events. This indicates the necessity of identifying
new molecular targets to limit platelet aggregation in diabetes
mellitus. In this regard, Rac1 could represent a good
candidate able to modulate both endothelial function and
platelet aggregation. Recently, a small molecule able to inhibit
Rac1 activity, named NSC23766, has been developed.13,14
NSC23766 has been shown to inhibit Rac1 activity by
interfering with its binding domain involved in the determina-
tion of Rac1’s specificity to a subset of guanine nucleotide
exchange factors that catalyze the exchange of GDP to GTP to
maintain Rac1 in its active, GTP-bound, form.14,15 Recently,
we have shown the beneficial effects of Rac1 inhibition
through NSC23766 on endothelial dysfunction in human
vessels.16 However, the mechanisms by which NSC23766
exerts its protective role on endothelial function in hyper-
glycemia are still partially unknown.
Rho-associated coiled-coil serine/threonine kinase-1
(ROCK1) is the main downstream target of the small GTPase
RhoA and has been involved in the regulation of multiple
cellular functions involving cytoskeletal organization.17 Given
the important role of Rac1 in endothelial and platelet function,
we hypothesized that ROCK1 might represent a potential
downstream target of Rac1 activity.
To better understand the role of Rac1 in diabetes mellitus,
we investigated the possible therapeutic role of NSC23766 on
vascular and platelet alteration using both in vitro and ex vivo
approaches in preclinical model of diabetes mellitus and
human samples.
Methods
The data, analytic methods, and study materials will be made
available to other researchers for purposes of reproducing the
results or replicating the procedure on request to corre-
sponding authors. All experiments involving animals were
conformed to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health
(publication 85-23, revised 2011) and were approved by the
Istituto di Ricovero e Cura a Carattere Scientifico Istituto
Neurologico Mediterraneo Neuromed review board. Human
subjects were enrolled at the Cardiology Division of the
University of Naples Federico II. The study protocol was
conformed to the principles outlined in the Declaration of
Helsinki and was approved by the institutional review board of
the medical center, and each patient who accepted to
participate provided written informed consent. All diabetic
patients enrolled in our study fulfilled the criteria of the






Age, y 56.35.03 57.052.39
Women, % 36 30
Hypertension, % 40 35
Hyperlipidemia, % 22 25
BMI, kg/m2 24.171.1 26.131.12
Smoking, % 46 45









Other antiplatelet agents 0 0
Data are represented as meanSD unless otherwise indicated. ACEI indicates
angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASA,
acetylsalicylic acid; BB, b blocker; BMI, body mass index; CCB, calcium channel blocker;
and HbA1c, glycated hemoglobin.
*P=0.00012 vs control subjects.
Clinical Perspective
What Is New?
• The molecular mechanisms that govern endothelial dys-
function and enhanced platelet aggregation in diabetes
mellitus are not completely elucidated.
• Herein, we show that Rac1 participates in diabetes mellitus–
induced platelet alterations and endothelial dysfunction.
What Are the Clinical Implications?
• Rac1 inhibition reduces platelet hyperactivity and endothe-
lial dysfunction in diabetes mellitus.
• Therefore, Rac-1 could represent a potential therapeutic
target to ameliorate both pathophysiological alterations in
diabetes mellitus.
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National Diabetes Data Group for diabetes mellitus.18 Char-
acteristics of patients (demographics, concomitant medica-
tion therapy, and glycemic status) are summarized in the
Table and Table S1. An expanded description of materials and
methods used in this study is available in Data S1.
Statistical Analysis
Data are presented as bar graphs, box-and-whisker plots, or
points and connecting line. Plots show mean, and the error
bars represent SEM. Different data sets were generated to
test differences in the experiments involving animals/cells or
humans. In the animal/cells study, differences were analyzed
by Mann-Whitney nonparametric test to compare 2 indepen-
dent groups or by Kruskal-Wallis test in experiments including
≥3 groups. For vascular reactivity studies, differences were
analyzed using nonparametric Friedman test, followed by
Dunn’s multiple comparison test, for the analysis of the
effects of the pharmacological treatments on vascular reac-
tivity function. Human data were presented as mean and SD
and analyzed by 2-tailed Student t test (Table). No random-
ization was applied to allocate patients in the different groups
because diabetic patients were chosen on the basis of
glycated hemoglobin percentage (baseline difference). There-
fore, no adjustment in the analysis was made because of the
baseline differences. No repeated measurements on the same
experimental unit over time were used. All experiments can be
considered on different experimental units. A minimum value
of P<0.05 was considered statistically significant. All statis-
tical analyses were conducted using GraphPad Prism software
7.0.
Results
Rac1 Inhibition Protects From Endothelial
Dysfunction in a Mouse Model of Diabetes
Mellitus
To evaluate the effects of NSC23766 on vascular function in
diabetes mellitus, we used a previously described mouse
model of streptozotocin-induced diabetes mellitus.19 Mesen-
teric arteries were isolated from streptozotocin-treated mice
and their control (vehicle-injected) littermates after IP injec-
tion of NSC23766 (5 mg/kg, as previously described),20,21 at
different time points (6, 12, 24, 36, 48, and 96 hours after
injection) to perform vascular reactivity studies (Figure 1A
through 1F). No effects on blood glucose levels and body
weight were found after NSC23766 treatment in both control
and streptozotocin-treated mice (Table S2).
As expected, diabetes mellitus caused impaired endothelial
vasorelaxation, as demonstrated by reduced response to
acetylcholine in mesenteric arteries of mice treated with
streptozotocin (Figure 1). In contrast, smooth muscle relax-
ation induced by nitroglycerine was unaffected by diabetes
mellitus (data not shown). Interestingly, in vivo administration
of NSC23766 in streptozotocin-treated mice reduced
endothelial dysfunction, ameliorating vasorelaxation starting
after 6 hours from injection, with a sustained effect present
up to 96 hours after administration (Figure 1A through 1F).
As expected, diabetic arteries also exhibited increased
ROS production and Nox activity (Figure 2A). We also
observed that, in streptozotocin-treated mice, both mRNA
and protein levels of ROCK1 were increased (Figure 2B and
2C), coupled with significant downregulation of phosphoinosi-
tide 3-kinase/protein kinase B signaling pathway (Figure 2C).
Interestingly, NSC23766 treatment abolished Rac1 activation
in diabetic vessels, which, in turn, reduced RhoA and ROCK1
levels, restoring the phosphoinositide 3-kinase/protein kinase
B signaling pathway and endothelial NO synthase (eNOS)
phosphorylation (Figure 2B). These data support the role of
Rac1 as an upstream modulator of ROCK1 involved in eNOS
dysfunction and ROS production in diabetes mellitus.
NSC23766 Prevents High Glucose–Induced
Endothelial Dysfunction by Restoring eNOS
Phosphorylation and Reducing Oxidative Stress
To evaluate the in vitro effects of NSC23766 on glucose-
induced endothelial dysfunction, mesenteric arteries from
wild-type C57BL/6 mice were treated with 2 different glucose
concentrations, mimicking normoglycemia (5 mmol/L) or
hyperglycemia (25 mmol/L). Vessels exposed to 25 mmol/
L of glucose for 30 minutes showed a significant reduction of
acetylcholine-evoked vasorelaxation compared with vessels
treated with 5 mmol/L of glucose (Figure 3A), whereas no
differences between the 2 different doses of glucose were
found in nitroglycerine-induced vasorelaxation (Figure S1).
These data confirm the detrimental effects of high glucose
levels on vascular function. Interestingly, pretreatment with
Rac1 inhibitor, NSC23766 (30 lmol/L), was able to protect
from endothelial dysfunction induced by high glucose (Fig-
ure 3A), restoring eNOS phosphorylation and reducing ROS
production and Nox activity (Figure 3B and 3C).
ROCK1 Is Involved in Rac1-Dependent Effects on
Vascular Function
It has been reported that Rac1 negatively modulates eNOS
function.22 This mechanism appears to be likely mediated by
the reduction of ROCK1, a negative regulator of eNOS. In fact,
ROCK1 inhibits eNOS gene expression and inhibits phospho-
inositide 3-kinase/protein kinase B signaling, which phos-
phorylates and activates eNOS.23,24 Accordingly, vessels
treated with high glucose concentration in presence of
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LY27632, an inhibitor of ROCK1 activity, showed increased
eNOS phosphorylation and enhanced vasorelaxation com-
pared with vessels treated with high glucose alone (Figure 3B
and 3D). Notably, in LY27632-treated vessels, Rac1 was still
activated, positioning it as an upstream modulator of ROCK1
(Figure 3B). Although the administration of Rac1 inhibitor in
presence of LY27632 did not further enhance eNOS phos-
phorylation compared with LY27632 alone (Figure 3B), at
functional level it was able to potentiate endothelial vasore-
laxation, suggesting that additional mechanism(s) are
recruited by Rac1 inhibitor to modulate endothelial function
(Figure 3D). Interestingly, in the same model of hyper-
glycemia-induced vascular damage, inhibition of Rac1 but
not inhibition of ROCK1 was able to protect the arteries from
high glucose–induced ROS generation, as shown by a
significant reduction in Nox levels after treatment with
NSC23766 (Figure 3C).
To better evaluate the contribution of ROS in the differ-
ential response on vascular function observed with Rac1 and
ROCK1 inhibitors, the antioxidant agent tiron (103 mol/L), a
superoxide scavenger, was used in addition to ROCK1
inhibitor. Treatment with tiron+LY27632 restored endothelial
vasorelaxation at similar level observed in presence of Rac1
inhibitor (Figure 3E). On the contrary, the addition of tiron to
NSC23766 did not influence the vascular response evoked by
Rac1 inhibition in presence of high glucose levels, whereas
Figure 1. NSC23766 restores relaxation in diabetic vessels. Acetylcholine (ACh) vasorelaxation in preconstricted mesenteric arteries from
vehicle-treated mice (control [Ctrl]; full circles), streptozotocin-treated mice (STZ; empty circles), from Ctrl mice treated with Rac1 inhibitor
(Ctrl+NSC23766; full squares), and from STZ-treated mice plus Rac1 inhibitor (STZ+NSC23766; empty squares) at different time points from
single injection of NSC23766: 6 hours (A), 12 hours (B), 24 hours (C), 36 hours (D), 48 hours (E), and 96 hours (F). n=4 for each group.
*P<0.05 vs all.
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treatment with tiron alone only partly ameliorated vascular
relaxation, accordingly with its scavenger effects (Figure 3E).
Given the striking reduction of ROS production and Nox
activity observed after NSC23766 treatment, we aimed to
determine the individual contribution of different Nox iso-
forms in glucose-induced ROS generation. Interestingly, the
use of Nox4 inhibitor, GTK137831, significantly decreased
ROS production and Nox activity in glucose-treated vessels
(Figure 3C), whereas no effects were observed after treat-
ment with Nox1 inhibitor, ML-171 (Figure 3C). We also
observed that Nox4 inhibition by GTK137831 partially
restored acetylcholine-induced vasorelaxation in mesenteric
arteries treated with high glucose dose (Figure 3F). Interest-
ingly, treatment of dysfunctional vessels with Nox1 inhibitor
ML-171 did not improve vascular reactivity (Figure 3F). These
data demonstrate a specific involvement of Nox4 isoform in
glucose-induced ROS production and suggest that the
observed vascular antioxidant effects of NSC23766 could
be mediated, at least in part, by the inhibition of Nox4 isoform
of Nox.
The beneficial effects of Rac1/ROCK1 inhibition on
glucose-induced endothelial dysfunction and ROS production
observed in the whole vessels were also observed in human
endothelial cells (Figure S2). Collectively, these data demon-
strate that ROCK1 inhibition ameliorates, in part, hyper-
glycemia-induced endothelial dysfunction without affecting
ROS production, whereas the improvement of endothelial
function observed with Rac1 inhibitor is also attributable to its
inhibitor effect on Nox, primarily on Nox4 isoform, reducing
ROS production.
Figure 2. NSC23766 restores endothelial NO synthase (eNOS) function and reduces reactive oxygen species in diabetic vessels. A,
Representative micrographs of Dihydroethidium staining to evaluate oxidative stress in mesenteric arteries from mice treated with vehicle
(control [Ctrl]), with streptozotocin (STZ), or with streptozotocin plus NSC23766 (STZ+NSC23766; 48 hours). Representative images (n=3).
Columns represent the effect of NSC23766 on nicotinamide adenine dinucleotide phosphate (NADPH)–induced lucigenin chemiluminescence in
STZ mice mesenteric arteries. Data are expressed as increase of chemiluminescence per minute in arbitrary units. n=4 for each group. *P<0.05 vs
all. B, The mRNA levels of Rho-associated coiled-coil serine/threonine kinase-1 (ROCK1) were determined by quantitative reverse transcription–
polymerase chain reaction in vessels from Ctrl, STZ, and STZ+NSC23766, 48 hours. n=3 for each group. *P<0.05. C, Representative
immunoblots (left) and densitometric analysis (right) of 4 independent experiments evaluating protein levels of ROCK-1, phospo (p)-eNOS, eNOS,
p-phosphoinositide 3-kinase (PI3K), PI3K, p-protein kinase B (Akt; T473), Akt, p21 activated kinase, RhoA-GPT, RhoA, Rac1-GTP, Rac1, and b-actin
in mesenteric arteries from Ctrl, STZ, and STZ+NSC23766 mice, 48 hours. n=3 for each group. *P<0.05.
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Rac1 Inhibition Restores NO Production in High
Glucose–Treated Human Platelets
Treatment of human platelets with high glucose concentration
(25 mmol/L) induced a strong activation of Rac1 and a
significant reduction of eNOS phosphorylation (Figure 4A).
Interestingly, administration of LY27632 restored eNOS
phosphorylation without affecting Rac1 activation (Figure 4A),
posing Rac1 as an upstream modulator of ROCK1 signaling
also in platelets. In addition, NSC23766 was also able to
restore eNOS phosphorylation, in presence of high glucose, at
similar levels compared with LY27632, whereas coadminis-
tration of both Rac1 and ROCK1 inhibitors did not further
modify eNOS phosphorylation status (Figure 4A). These data
suggested that the effect of NSC23766 on eNOS phospho-
rylation is mediated by ROCK1.
Reduced platelet NO production represents a crucial
alteration in diabetes mellitus. As expected, we observed a
dramatic impairment of NO release in the supernatants of
platelets exposed to high glucose concentration compared
with platelets exposed to low glucose, measured by Sievers NO
analyzer (NOA280i) (Figure 4B). To confirm the specificity of
Figure 3. Interplay between RAC1 and Rho-associated coiled-coil serine/threonine kinase-1 in vessels and platelets. A, Acetylcholine (ACh)
vasorelaxation in preconstricted mesenteric arteries treated with low glucose (Glu; 5 mmol/L; full circles), high glucose (Glu 25 mmol/L; empty
circles), low glucose plus Rac1 inhibitor (Glu 5 mmol/L+NSC23766; full squares), and high glucose plus Rac1 inhibitor (Glu 25 mmol/
L+NSC23766; empty squares). n=4 for each group. *P<0.05 vs all. B, Representative immunoblots (left) and densitometric analysis (right) of 4
independent experiments evaluating protein levels of p-endothelial NO synthase (eNOS), eNOS, Rac1-GTP, total Rac1, and b-actin in mesenteric
arteries treated with Glu 5 mmol/L, Glu 25 mmol/L, Glu 25 mmol/L plus LY27632 (Glu 25 mmol/L+LY27632), Glu 25 mmol/L+NSC23766,
or Glu 25 mmol/L+NSC23766+LY27632. *P<0.05 vs all; *P<0.05 vs Glu 5 mmol/L, Glu 25 mmol/L+NSC23766, and Glu 25 mmol/
L+NSC23766+LY27632. C, Representative images of Dihydroethidium staining to evaluate oxidative stress in mesenteric arteries treated with
different stimuli/inhibitors. Columns represent the effect of NSC23766, LY27632, GKT137831, and ML-171 on nicotinamide adenine
dinucleotide phosphate (NADPH)–induced lucigenin chemiluminescence in mice mesenteric arteries. Data are expressed as increase of
chemiluminescence per minute in arbitrary units. n=4 for each group. *P<0.05. D, ACh vasorelaxation in preconstricted mesenteric arteries
from control treated with Glu 5 mmol/L, Glu 25 mmol/L, Glu 25 mmol/L+LY27632, Glu 25 mmol/L+NSC23766, and Glu 25 mmol/
L+NSC23766+LY27632. n=4 for each group. *P<0.05 vs Glu+LY27632; #P<0.05 vs Glu 5 mmol/L, Glu 25 mmol/L+NSC23766, and Glu
25 mmol/L+NSC23766+LY27632; §P<0.05 vs Glu 5 mmol/L, Glu 25 mmol/L+NSC23766, and Glu 25 mmol/L+NSC23766+LY27632. E, ACh
vasorelaxation in preconstricted mesenteric arteries from mesenteric arteries treated with Glu 5 mmol/L, Glu 25 mmol/L, Glu 25 mmol/
L+LY27632, Glu 25 mmol/L+LY27632+tiron, Glu 25 mmol/L+NSC23766+tiron, and Glu 25 mmol/L+tiron. n=3 for each group. *P<0.05 vs
Glu 25 mmol/L+LY27632; #P<0.05 vs Glu 5 mmol/L, Glu 25 mmol/L+LY27632+tiron, and Glu 25 mmol/L+NSC23766+tiron; §P<0.05 vs Glu
5 mmol/L, Glu 25 mmol/L+LY27632+tiron, and Glu 25 mmol/L+NSC23766+tiron; °P<0.05 vs Glu 5 mmol/L, Glu 25 mmol/
L+LY27632+tiron, and Glu 25 mmol/L+NSC23766+tiron. F, ACh vasorelaxation in preconstricted mesenteric arteries from vessels treated
with Glu 25 mmol/L, Glu 25 mmol/L plus ML-171 (Glu 25 mmol/L+ML-171), or Glu 25 mmol/L plus GTK137831 (Glu 25 mmol/
L+GTK137831. n=5 for each group. *P<0.05 vs Glu25 mmol/L+GTK137831; #P<0.05 vs Glu 25 mmol/L+ML-171.
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NO production, we also measured NO levels in supernatant of
platelets treated with NOS inhibitor Nx-nitro-L-arginine methyl
ester hydrochloride. As shown in Figure 4B, Nx-nitro-L-
arginine methyl ester hydrochloride treatment completely
abolished NO production in platelet supernatant. Interestingly,
treatment with Rac1 inhibitor NSC23766 restored platelet NO
production, whereas treatment of high glucose–stimulated
platelets with ROCK1 inhibitor was able to restore only, in part,
the impaired NO production (Figure 4B). Similar to what was
observed in vessels, addition of tiron to high-glucose platelets
treated with LY27632 further enhanced NO production to the
levels observed with Rac1 inhibitor NSC23766 (Figure 4B).
Human platelet supernatant evoked a rapid dose-depen-
dent relaxation of mouse aortic rings; this effect was NO
dependent because it was abolished by eNOS inhibition with
Nx-nitro-L-arginine methyl ester hydrochloride (Figure 4C). As
expected, the effect on vasorelaxation induced by platelet
supernatant was markedly reduced by high glucose level
(25 mmol/L) compared with vessels treated with supernatant
of platelets with low dose of glucose (5 mmol/L) (Figure 4C),
Figure 4. Rac1 inhibition restores NO release from platelets. A, Representative immunoblots (left) and densitometric analysis (right) of 4
independent experiments evaluating protein levels of p-endothelial NO synthase (eNOS), eNOS, Rac1-GTP, total Rac1, and b-actin in platelets.
*P<0.05 vs all. B, Quantitative measurement of NO levels in platelet supernatants treated with glucose 5 mmol/L (Glu 5 mmol/L), Glu 5 mmol/
L+Nx-nitro-L-arginine methyl ester hydrochloride (L-NAME), glucose 25 mmol/L (Glu 25 mmol/L), Glu 25 mmol/L plus NSC23766 (Glu
25 mmol/L+NSC23766), Glu 25 mmol/L plus LY27632 (Glu 25 mmol/L+LY27632), Glu 25 mmol/L plus NSC23766 plus LY27632 (Glu
25 mmol/L+NSC23766+LY27632), and Glu 25 mmol/L plus LY27632 plus tiron (Glu 25 mmol/L+LY27632+tiron). Box plots representing the
mean and the minimum and maximum values of NO amounts. n=4 for each group. *P<0.05 vs all; #P<0.05 vs Glu 25 mmol/L+NSC23766, Glu
25 mmol/L+NSC23766+LY27632, Glu 5 mmol/L, and Glu 25 mmol/L. C, Dose-response curves of phenylephrine precontracted aorta rings to
supernatants derived from human platelets treated with Glu 5 mmol/L, Glu 5 mmol/L+L-NAME, and Glu 25 mmol/L. n=4 for each group.
*P<0.05 vs Glu 5 mmol/L. D, Dose-response curves of phenylephrine precontracted aorta rings to supernatants derived from human platelets
treated with Glu 5 mmol/L, Glu 25 mmol/L, Glu 25 mmol/L+NSC23766, Glu 25 mmol/L+LY27632, Glu 25 mmol/L+NSC23766+LY27632,
Glu 25 mmol/L+LY27632+tiron, or Glu 25 mmol/L+tiron. n=4 for each group. *P<0.05 vs all; §P<0.05 vs Glu 25 mmol/L+LY27632; §P<0.05
vs Glu 25 mmol/L+NSC23766; #P<0.05 vs all.
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confirming the effects of high glucose to induce an impair-
ment in the NO-dependent vasorelaxant mechanisms.
To evaluate the role of Rac1/ROCK1 axis in platelet-induced
NO-dependent vasorelaxation, supernatants from NSC23766
or ROCK1 inhibitor LY27632-treated platelets were used on
mouse aortic ring preparations. Interestingly, treatment of
platelets with NSC23766 restored the ability of platelet
supernatant to induce a dose-dependent relaxation of mouse
aortic rings in presence of high glucose levels (Figure 4D),
whereas the supernatant of LY27632-treated platelets was
able to ameliorate only, in part, vasorelaxation (Figure 4D).
Interestingly, the addition of tiron caused an enhancement of
vasorelaxant effect observed with supernatant of LY27632-
treated platelets, reaching a similar level on what was observed
in presence of NSC23766 alone or NSC23766 plus LY27632
(Figure 4D). The administration of tiron alone exerted only a
mild, not significant, improvement of vasorelaxation.
Taken together, these results indicated that the effect of
Rac1 inhibitor on NO metabolism in presence of high glucose
levels depends on the modulation of both eNOS phosphory-
lation and oxidative stress.
NSC23766 Reduces Platelet Aggregation Induced
by High Glucose Levels
Because impairment of NO production is closely associated
with an increase of platelet reactivity, we investigated the
effect of Rac1 inhibitor on human platelet aggregation. As
expected, platelet aggregation induced by type I collagen was
enhanced after treatment with increasing concentrations of
glucose (Figure 5A). Subsequently, we aimed to identify the
effective concentration of NSC23766 able to modulate
platelet aggregation. We performed a dose-response curve
with NSC23766 in human platelets exposed to 5 and
25 mmol/L of glucose. In platelets exposed to 5 mmol/L
(mimicking “normoglycemic” condition), the effective dose to
reach a significant inhibition of platelet aggregation was
30 lmol/L, whereas further increase in NSC23766 dose
(starting from 50 lmol/L) practically abolished any collagen-
induced aggregation (Figure 5B). Interestingly, when the same
dose-response curve was done exposing platelets to
25 mmol/L of glucose (mimicking “hyperglycemic” condi-
tion), an increased sensitivity to Rac1 inhibition was observed.
Specifically, under this condition, the inhibitory effect of
NSC23766 on platelet aggregation appeared already at the
dose of 15 lmol/L, decreasing further at 30 lmol/L (Fig-
ure 5B). Similar results were obtained when platelets were
stimulated with different agonists, such as arachidonic acid
(0.5 mmol/L), ADP (50 mmol/L), or thrombin receptor-
activating peptide (25 lmol/L) (data not shown). These
results suggest that glucose per se can prime platelets,
making them more susceptible to the effects of NSC23766,
and that Rac1 hyperactivity played a pivotal role in the
modulation of high glucose–induced platelet aggregation.
Moreover, to demonstrate that Rac1 effects on glucose-
dependent platelet aggregation were not dependent by
changes in platelet osmolarity, we evaluated platelet aggre-
gation after increasing dose of osmotic-control mannitol with
and without NSC23766. The administration of mannitol did
not change platelet reactivity, confirming the specific role of
glucose to induce platelet hyperaggregation (Figure S3).
Accordingly, platelet Rac1 levels did not show any change
after mannitol treatment (Figure S3).
Finally, we investigated the potential role of ROCK1 in
modulation of platelet aggregation during hyperglycemic
conditions. Differently from what was observed in vessels,
ROCK1 inhibition by LY27632 in platelets did not affect
platelet aggregation in presence of both high glucose or low
glucose concentrations (data not shown), confirming the
marginal role of ROCK1 in modulation of platelet aggregation,
as observed before.25
Platelets From Diabetic Patients Show Increased
Levels of Activated Rac1
To translate our results into a clinical setting, we evaluated
active Rac1 levels in platelets isolated from diabetic patients
and control subjects without diabetes mellitus (Table). Platelets
from diabetic patients showed higher levels of activated Rac1
compared with control samples (Figure 6A and 6B).
It is well known that in diabetes mellitus, platelets are
hyperreactive, with intensified adhesion, activation, and
aggregation.26 Thus, we evaluated the level of activated
Rac1 in platelets from diabetic patients accordingly with their
reported percentage of glycated hemoglobin. Interestingly,
our pull-down assay showed a higher level of active Rac1 in
platelets from patients with elevated percentage of glycated
hemoglobin (10%) compared with those with lower glycated
hemoglobin (7%), indicating a correlation between diabetes
mellitus status and Rac1 activation (Figure 6A and 6B).
Moreover, to evaluate the effect of diabetes mellitus on
platelets, we evaluated platelet aggregation in diabetic
patients. As expected, under basal condition, the aggregation
induced by collagen was enhanced in platelets from diabetic
patients compared with control subjects (Figure 6C, left
panel). Next, we evaluated the efficacy of NSC23766 to inhibit
collagen-induced platelet activation in diabetic patients.
Interestingly, to obtain a significant reduction in diabetic
platelet aggregation, a higher dose of NSC23766 was
necessary compared with control platelets (60 in comparison
to 30 lmol/L already effective in platelets from control
subjects) (Figure 6C, middle panel).
Although platelets exposed to increasing concentration of
glucose exhibit an increased sensitivity to Rac1 inhibition
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(Figure 5B), higher doses of Rac1 inhibitor were necessary to
reach the same levels of inhibition of aggregation in platelets
isolated from diabetic patients (Figure 6C, middle panel). To
rule out the potential off-target effects of NSC23766
observed when used at high concentrations,27 we used
another structurally different Rac1 inhibitor, called EHT1864.
As shown in Figure S4, also with EHT1864, a higher dose of
inhibitor was necessary to significantly reduce platelet
aggregation in diabetic conditions compared with control
subjects.
NSC23766 Exerts Additive Effect on Platelet
Aggregation From Diabetic Patients Treated With
Acetylsalicylic Acid
On the basis of the evidence that several diabetic patients
showed a resistance to common antiplatelet drugs, such as
acetylsalicylic acid (ASA), we decided to investigate the
efficacy of NSC23766 treatment in isolated platelets from
ASA-treated diabetic patients. In particular, we tested
increasing concentrations of NSC23766 on platelets from
diabetic patients treated with ASA, 100 mg/d. Interestingly,
in this experimental condition, NSC23766 treatment was able
to further reduce the platelet aggregation in diabetic patients
already treated with ASA (Figure 6C, right panel).
Discussion
We found that pharmacological inhibition of Rac1 by
NSC23766 attenuated endothelial dysfunction in experimen-
tal model of diabetes mellitus and reduced platelet hyperag-
gregation in diabetic patients. These novel results suggest a
potential protective role of Rac1 inhibition on vascular injury
and platelet hyperaggregation in diabetes mellitus.
Figure 5. NSC23766 inhibits glucose-induced platelet hyperaggregation. A, Quantification of platelet
aggregation presented as percentage of light transmission of platelets from control (CTRL) subjects treated
with increasing concentrations of glucose (Glu). n=6 independent experiments from individual subjects.
*P<0.05 vs glucose 5 mmol/L. B, Quantification of platelet aggregation presented as percentage of light
transmission of platelets from CTRL subjects treated with increasing concentrations of NSC23766 at 5 and
25 mmol/L Glu. n=4 independent experiments from individual subjects. *P<0.05 vs Glu 5 mmol/L without
NSC23766; #P<0.05 vs Glu 5 mmol/L with NSC23766 30 lmol/L; §P<0.05 vs Glu 25 mmol/L without
NSC23766; †P<0.05 vs Glu 25 mmol/L with NSC23766 15 lmol/L and Glu 5 mmol/L with NSC23766
30 lmol/L.
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Rac1 is a regulatory component of Nox, which represents 1
of the major sources of ROS in the vascular wall. ROS
generation is crucially involved in diabetes mellitus and
diabetic complications.28 Although many sources of ROS
contribute to increased oxidative stress in diabetes mellitus
(direct effect of hyperglycemia, mitochondria, and xanthine
oxidase), several Nox isoforms have been found specifically
upregulated in vascular wall in the presence of high
glucose.29,30 We have previously shown that Rac1 represents
a crucial modulator of ROS-induced vascular dysfunction in
preclinical model of diabetes mellitus.19 Its inhibition by an
adenoviral vector carrying Rac1 dominant negative mutant
protects from endothelial dysfunction in experimental dia-
betes mellitus.19 In the past decade, NSC23766 was identi-
fied as a small-molecule inhibitor of Rac–guanine nucleotide
exchange factor–mediated activation of Rac1.14,15 Until now,
its main field of application has been cancer biology, in which
Rac1 has been reported as a novel important therapeutic
target in several type of malignancies.31–35 Given the growing
importance of Rac1 in the cardiovascular system, recently
NSC23766 has been tested in different cardiovascular
disorders.22
Herein, we have shown the protective effects of Rac1
inhibitor, NSC23766, on endothelial function after high
glucose–induced vascular damage. Mechanistically, we
demonstrated that amelioration of endothelial function via
restoration of eNOS phosphorylation by Rac1 inhibition
requires ROCK1 as a crucial component of Rac1 signaling in
both isolated cells and vessels. Although previous studies
have suggested a reduction in eNOS expression after Rac1
inhibition,36 the modulation of Rac1 activity by NSC23766 in
our study was not related to changes in its expression in both
mouse vessels and human endothelial cells. Moreover, we
were recently able to demonstrate that Rac1 inhibition by
NSC23766 exerts a beneficial effect also in human vessels,
ameliorating endothelial dysfunction.16 These results pointed
out the important role of Rac1 as a therapeutic target to
improve vascular homeostasis.
Figure 6. NSC23766 ameliorates platelet hyperaggregation in diabetes mellitus. A, Representative immunoblots of Rac1-GTP and Rac1 levels
in platelets from control (CTRL) subjects or diabetic (Db) patients with different percentage of glycated hemoglobin (HbA1c). GAPDH protein
levels were used for normalizing samples. B, Densitometric analysis of Rac1-GTP (left) and Rac1 (right) protein levels in platelet samples from
CTRL and Db patients. n=4 independent experiments from individual subjects. *P<0.05 vs all; #P<0.05 vs CTRL; §P<0.05 vs Db HbA1c 7.0%. C,
Quantification of platelet aggregation presented as percentage of light transmission of CTRL platelets (left), Db platelets (middle), and Db
platelets+acetylsalicylic acid (ASA) treated with NSC23766. n=4 independent experiments from individual subjects. *P<0.05 vs CTRL 0 (without
NSC23766); #P<0.05 vs Db 0 (without NSC23766); §P<0.05 vs CTRL, Db 0, and Db+ASA 0 (without NSC23766). IB indicates immunoblot; NC,
negative control; and PC, positive control.
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Levay et al27 have demonstrated an effect of NSC23766
as nonselective competitive antagonist of muscarinic acetyl-
choline receptors in neonatal rat cardiomyocytes. In our
experimental model on resistance vessels, we were able to
show that NSC23766 per se did not interfere with acetyl-
choline vasorelaxation (Figure S5). Consistently with other
studies, we have demonstrated that the activation of Rac1
(Rac1-GTP) negatively modulates eNOS phosphorylation
through ROCK-1 pathway.37,38 In addition to its effect on
eNOS phosphorylation, inhibition of Rac1 also blunted Nox
ROS production. Hence, these data demonstrated that the
amelioration of endothelial relaxation obtained by Rac1
inhibition in presence of high glucose levels depends on 2
mechanisms: the increased eNOS phosphorylation and the
reduction of oxidative stress.
These data prompted us to explore the effects of Rac1
inhibitor in a mouse model of diabetes mellitus. NSC23766
treatment reduced the enhanced Rac1 activation observed in
preclinical diabetes mellitus and restored acetylcholine-
evoked vasorelaxation. Interestingly, amelioration of endothe-
lial function observed after Rac1 inhibition in vessels from
diabetic mice was present up to 96 hours after NSC23766
systemic administration and, accordingly, we observed a
sustained inhibition of Rac1 activity in mice vessels at the
same time point (Figure S6). Reduction of ROS production in
diabetic vessels treated with NSC23766 can be attributed to
reduction in Nox activity. Although, given the complexity of
ROS production in diabetes mellitus, previously discussed, it
is likely that Nox might not be the only target of Rac1
inhibition. Using pharmacological inhibition of the different
Nox isoform, we were able to identify Nox4 as a critical
component of NSC23766-mediated ROS suppression in
vascular wall. These data will serve as a platform to pursue
more in-depth mechanistic insights in Rac1/Nox4 interaction.
In addition to vascular damage, diabetes mellitus is also
characterized by platelet dysfunction. Previous studies
reported that high levels of glucose were able to increase
platelet aggregation in vitro and were associated with ROS
production.39 Rac1 is involved in platelet actin cytoskeleton
reorganization during platelet activation. A crucial feature of
platelets is represented by their ability to produce NO. Our
data demonstrate that high glucose levels activate Rac1 in
platelets, and this effect is associated with an impaired NO
release. Notably, similar to what was observed in vessels and
endothelial cells, the administration of NSC23766 in platelets
protects from the deleterious effect of high glucose on NO
metabolism, enhancing eNOS phosphorylation, through
ROCK-1 inhibition, and blunting oxidative stress. It is well
known that a reduction in NO release is coupled with
alteration in platelet activation. In this regard, 1 of the most
striking changes that occur during platelet activation is the
translocation of CD62 (P-selectin) protein to the outer platelet
membrane. Therefore, the expression of CD62 on the
membrane of platelets is considered to be a valuable indicator
for platelet activation in different diseases, including diabetes
mellitus.40,41 To evaluate the effects of NSC23766 on platelet
activation in diabetes mellitus, we performed the immunoblot
analysis of CD62 expression in cytosol and membrane
subcellular fraction of platelets isolated from diabetic (strep-
tozotocin-treated) and control mice in presence and absence
of NSC23766. As shown in Figure S7, membrane expression
of CD62 in diabetic platelets was significantly increased. More
important, in vivo administration of NSC23766 in diabetic
mice abolished CD62 membrane translocation in platelets,
demonstrating a significant reduction of platelet activation on
Rac1 inhibition. These data suggest that the effects of
NSC23766 on platelet function in diabetes mellitus are
potentially beyond the expected cytoskeleton reorganization
and might contribute to the beneficial effects observed in vitro
and in vivo, corroborating our previous results.
Interestingly, herein we have shown that Rac1 is respon-
sive to high glucose levels, enhancing platelet aggregation,
acknowledging Rac1 as an important regulator of platelet
function during hyperglycemic conditions. We demonstrated
that a condition mimicking hyperglycemia in vitro increases
platelet Rac1 activation. On the basis of this result, we
hypothesized that increased active Rac1 platelet levels under
hyperglycemic conditions could contribute to the increased
platelet activity observed in diabetes mellitus. Using a specific
inhibitor of Rac1 activity, NSC23766, we demonstrated that
glucose-induced platelet hyperaggregation was reduced. The
increased efficacy of NSC23766 to inhibit platelet aggrega-
tion in hyperglycemic state could be explained by increased
Rac1 GTP levels under this condition. The effect of glucose on
platelet aggregation starts to appear for concentration of
glucose of 25 mmol/L and seems to be sustained even with
higher concentration (50 mmol/L), suggesting the presence
of a threshold for glucose-induced hyperaggregation in human
platelets. Under normal glucose condition, the dose of
30 lmol/L, NSC23766 was sufficient to reduce Rac1 activity,
modulating, in turn, platelet function. Although the dose used
in our study was significantly lower compared with the one
used elsewhere,42 we cannot completely exclude that the
potential off-target effects of NSC23766 might affect our
results. Because the effect of NSC23766 on platelet aggre-
gation, under high glucose condition, is already present for
lower NSC23766 doses (15 lmol/L), this raised the question
of how to separate the effect of hyperglycemia and the effect
of NSC23766 on platelet aggregation. In our experiments, we
chose relatively high levels of glucose (25 and 50 mmol/L) to
mimic hyperglycemic conditions. Indeed, these levels of
hyperglycemia are clinically relevant, because blood glucose
commonly increases at 30 mmol/L in diabetic ketoacidosis
and can reach 60 mmol/L during diabetic hyperosmolar
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coma.43 Therefore, during hyperglycemic condition, even a
small increase in platelet aggregation can significantly worsen
the clinical conditions. In our experiments, we recorded an
increase of 10% in platelet aggregation on hyperglycemic
stimuli using light transmission aggregometry. This increase
is consistent with previous literature using the same
technique,39 although it can be smoothened by the fact that
the baseline percentage of platelet aggregation in our
subjects is higher compared with previous reports. We
speculated that this effect can be attributable to the fact
that the control population is not represented by completely
“healthy” subjects because, despite being free from cardio-
vascular disease and diabetes mellitus, they present some
cardiovascular risk factors, such as hypertension and smok-
ing, that can contribute to the increased platelet reactivity.
Collectively, data from other groups and we suggest that
hyperglycemic condition produces a 10% to 20% increase in
platelet aggregation after stimulation with proaggregating
stimuli (ie, collagen) that can reflect, at least in part, the
prothrombotic state observed in diabetic patients.
Given the known off-target effect of NSC23766,42 it is
possible to speculate that glucose can prime platelets, making
them more susceptible to the effects of NSC23766. Accord-
ingly, in our model, Rac1 GTP is specifically induced by high
glucose in platelets, without osmotic effects, as demonstrated
by the absence of Rac1 activation with mannitol; therefore, the
mild effects of NSC23766 on platelet aggregation observed in
normoglycemic state might be caused by the low levels of Rac1
GTP in platelets. Accordingly, platelets from diabetic patients
showed a positive correlation between activated Rac1 and
levels of glycated hemoglobin. To provide further support that
Rac1 is a critical target in diabetic platelets, we used another
Rac1 inhibitor, called EHT1864. Differently from NSC23766,
which prevents the conversion of Rac1-GDP to Rac1-GTP by
competitively blocking the binding loop of Rac1-specific
guanine nucleotide exchange factors, EHT1864 is a specific
allosteric inhibitor of the Rac family, resulting in dissociation of
nucleotides.44 Using 2 different Rac1 inhibitors, we further
corroborate the notion that Rac1 plays a major role in platelet
proaggregating status in diabetes mellitus, underlying the
peculiar platelet characteristics of diabetic subjects.
It is important to underline that in condition of Rac1
hyperactivation (such as platelets from diabetic patients), a
higher dose of Rac1 inhibitor was necessary to reduce platelet
aggregation compared with platelets from subjects without
diabetes mellitus, pointing out that diabetes mellitus affects
platelet function in many ways, which are to be exclusively
recapitulated by increasing the concentrations of glucose
in vitro. We also found NSC23766 treatment further reduced
platelet aggregation in those subjects taking ASA, identifying
Rac1 inhibition as a potential future pharmacological strategy
to limit platelet hyperaggregation in diabetes mellitus. Unlike
diabetic patients without ASA in whom we were able to
recognize a dose-response curve of Rac1 inhibitory effects on
platelet aggregation, the additive effects of NSC23766 on
ASA-treated diabetic platelets were not dose dependent.
These effects could be attributed to the lower responsiveness
of platelets already treated with ASA. In fact, inhibition of
platelet aggregation by other mechanisms (such as cyclooxy-
genase-dependent mechanisms) could blunt the incremental
inhibitory effect of Rac1 inhibition.
Study Limitations
The beneficial effects of Rac1 inhibition on hyperglycemia-
induced vascular and platelet dysfunction observed ex vivo
need to be confirmed in ad hoc preclinical models of
thrombus formation and using tissue-specific genetic
approaches to distinguish between platelet- and endothelial
cell–driven effects. Nevertheless, the current findings suggest
that Rac1 inhibition may be accomplished directly in vivo
because of the favorable safety profile of NSC23766, as
observed in our mouse model of streptozotocin-induced
diabetes mellitus. Finally, the effects of LY27632 as ROCK1
inhibitor can be also attributed, in part, to the inhibition of
ROCK2, although recent studies have demonstrated that
ROCK1 and ROCK2 have distinct nonredundant functions and
have different targets in different cell types.45,46
Conclusions
The results of our study address an important challenge in
biological features of diabetes mellitus (namely, platelet
hyperreactivity and endothelial dysfunction). We provide
further evidence about the involvement of Rac1 in both
vascular injury and platelet hyperaggregation induced by
diabetes mellitus. Our findings could support the use of Rac1
inhibition by NSC23766 in combination with ASA for
antiplatelet therapy in diabetes mellitus. Although proposing
Rac1 inhibitor as an immediate therapeutic approach in
diabetic patients is far beyond the scope of our work, we
believe that the identification of targets/drugs able to
modulate >1 function in this disease could represent the
right way to move forward. In particular, the combination of
beneficial effects of Rac1 inhibition on both vascular and
platelet function in diabetes mellitus might represent a
potential effective strategy (in the future) to increase the
therapeutic compliance of these patients.
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All experiments involving animals were conform to the guidelines for the Care and Use of 
Laboratory Animals published from Directive 2010/63/EU of the European Parliament and were 
approved by IRCCS INM Neuromed review board (ref. number 1070/2015 PR). Diabetes was 
induced by four intraperitoneal injection (i.p. – once a day) of streptozotocin (STZ, 40 mg/kg body 
weight and dissolved in 0.1 M citrate buffer, pH 4.5) in male wild-type C57BL/6 mice (weighing 
approximately 25g). Control mice received citrate buffer alone (vehicle). Three days after the last 
injection of STZ, blood glucose levels were measured using glucose test strips (Roche) and mice with 
blood glucose at least 3-fold higher than the pre-injection level were used as diabetic mice. Mice were 
housed in groups (4–6 mice per cage) in a specific pathogen-free controlled environment (inverted 
12 h light cycle; lights off at 10:00 hours). All mice had free access to standard mice chow and water.  
The experiments were conducted after 4 weeks following the induction of diabetes. Animals that have 
not developed diabetes were excluded from the study. NSC23766 (Tocris Biosceince) was injected 
in mice i.p. at the dose of 5 mg/kg. This dose was chosen on the basis of a pilot study conducted in 
our laboratory and taking into account previously published data 1, 2. Mice were euthanized by 
intraperitoneal injection of 150 mg/kg Ketamine, 20mg/Kg xylazine.  
 
Human studies  
In our clinical study two population of patients were enrolled: 1) subjects without type-2 diabetes 
(CTRL, n=11) and 2) subjects with type-2 diabetes (Db, n=22). All the experiments used to evaluate 
platelets aggregation were carried in these two populations using the CTRL group as a reference. 
Table 1 describes the baseline characteristics of both populations. Subjects were enrolled at the 
Cardiology division of the University of Naples Federico II. The study protocol was approved by the 
institutional review board of the medical center, and each patient who accept to participate provided 
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Diabetes Data Group for diabetes 3. Diabetes developed in most of the patients after 40 years of age. 
None of the subject enrolled in both the two populations (CTRL and Db) had a history of coronary 
heart disease, recent myocardial infarction, unstable angina pectoris, heart failure, thyroid, renal, or 
hepatic disease. Pharmacological therapy is presented in Tale 1. A subgroup of 7 Db patients of the 
22 enrolled were treated with ASA 100 mg daily and platelets aggregation were performed on blood 
samples 14 days after treatment as described before.  
 
Vascular reactivity studies  
Vessels were placed in a wire myograph system filled with glucose-free Krebs solution. First, an 
analysis of vascular reactivity curves was performed. In particular, vasoconstriction was assessed 
with 80 mmol/L of KCl or with increasing doses of phenylephrine (from 10−9 M to 10−6 M) or U46619 
(10−11 M to 10−6 M), in control conditions. Vascular responses were then tested before and after 
glucose treatment (5-25 mM). Endothelium-dependent and -independent relaxation was assessed by 
measuring the dilatory responses of mesenteric arteries to cumulative concentrations of acetylcholine 
(from 10−9 M to 10−5 M) or nitroglycerine (from 10−9 M to 10−5 M), respectively, in vessels pre-
contracted with phenylephrine at a dose necessary to obtain a similar level of pre-contraction in each 
ring (80% of initial KCl-evoked contraction). Caution was taken to avoid endothelial damage; 
functional integrity was reflected by the response to acetylcholine (from 10−9 M to 10−6 M). Some 
studies were performed treating the vessels with NSC23766 (30 µmol/L) or with ML171 (0,5 µmol/L) 
or with GTK137831 (1 µmol/L) . Vascular relaxation is reported as percentage, considering basal 
tension before phenylephrine stimulus as -100% of vascular relaxation and phenylephrine-induced 











Commercially available human umbilical veins endothelial cells (HUVECs) were purchased from 
Lonza (Walkersville, MD, USA) and grown in EBM-2 basal medium. Cells were used within the five 
passage and at 70% confluence for the following sets of experiments. The cells were treated with 5 
mM or 25 mM of glucose for 24 hours, subsequently were treated with NSC23766 30µM or LY27632 
30µM for 30 minutes. For the western blot experiments, cells were treated with acetylcholine 100 
µmol/L for the last 15 minutes.  
 
Measurement of NADPH oxidase activity 
HUVECs was depleted of serum and prepared for the assay. Vessels were isolated and prepared 
for the assay. Cells were treated with 0 mM, 5 mM and 25 mM of glucose and then with NSC23766, 
30µM for 30 minutes. At the end of treatment (1 hours) cells were resuspended at 2 × 106 cells/ml 
confluency in aerated balanced salt solution. 1 × 106 cells/ml were used for the assay. Cells from 
various treatments were added to a scintillation vial containing lucigenin (5 μmol/L) in the aerated 
balanced salt solution. After a 5-minute dark adaptation, photon emission was measured for 10 min 
using the Beckman LS6500 Multipurpose Scintillation counter measuring single photon emission. 
First, photon emission was measured using a buffer blank and dark-adapted lucigenin. NADPH (100 
μmol/L) was added after measurement of background lucigenin chemiluminescence and 
measurements were performed for other 10 minutes. 
 
Platelet experiments  
Platelet isolation  
Venous blood was drawn from peripheral antecubital vein in fasting without refrain from smoking 
volunteers at University Federico II of Naples, who were free from medication known to interfere 
with platelet function (CTRL group). Other blood samples were drawn from diabetic patients free or 
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(PRP) was prepared from blood (about 15 ml) that was drawn by venipuncture into 3 ml of 3.8% 
trisodium citrate (w/v). PRP was obtained by centrifugation of blood at 150 g at 25°C for 15 minutes 
and was used as source of platelets. Platelet-poor plasma (PPP) was prepared from the residual blood 
by centrifugation of the rest of the blood at 1400 g at 25°C for 10 minutes. 
 
Study of vascular reactivity evoked by platelets supernatant 
Platelet pellets were produced by centrifugation of PRP at 900 g for 7 minutes, and re-suspended 
in Tyrode’s solution (132 mmol/L NaCl, 4 mmol/L KCl, 1.6 mmol/L CaCl2, 0.98 MgCl2 , 23.8 
mmol/L NaHCO3 , 0.36 mmol/L NaH2PO4 , 10 mmol/L glucose, 0.05 mmol/L Ca-Titriplex, and 
gassed with 95% O2 , 5% CO2 and pH 7.4 at 37 °C). After a further centrifugation step (900 g, 4 
minutes), washed platelets were re-suspended in the same solution, allowed to equilibrate for 10 
minutes at 37 °C and then stimulated with insulin (1 µmol/L) for 10 minutes. Some experiments were 
performed in platelets pre-treated with NG-nitro-L-arginine methyl ester (L-NAME) (300 µmol/L, 30 
minutes) for 30 minutes. After stimulation, the platelet suspension was centrifuged for 2 minutes at 
900g and increasing doses of supernatant (0.1-0.2-0.4-0.8 ml) was added to phenyleprine-
precontracted arteries mounted in an organ chamber (final volume, 15 ml). Total number and purity 
of platelets for each preparation was assessed by flow cytometry. Total protein from each preparation 
was also determined. Similar number of platelets (174±19x106/mL) between all samples was 
estimated. 
To test the vasorelaxant effect evoked by platelet supernatants, studies of vascular reactivity on 
isolated vessels from C57BL/6 mice were carried out. Four ring segments (3 mm width) of thoracic 
aorta from each mouse were mounted between stainless steel triangles in a water-jacketed organ bath 
(37°C) for measurement of tension development as previously described 4. Preliminary experiments 
demonstrated that the optimal resting tension for development of active contraction was 1g. Vessels 
were gradually stretched over one-hour period to this tension. The presence of functional endothelium 
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and nitroglycerine (10-9 to 10-5 mol/L) to induce the relaxation of vessels precontracted with 
phenylephrine (10-9 to 10-6 mol/L) to obtain a similar level of precontraction in each ring (80% of 
initial KCl-induced contraction). Responses to vasoconstrictors were examined at this resting tension 
and related to maximal vasoconstriction elicited by depolarization with 80 mmol/L KCl. Responses 
to vasodilator supernatants obtained from stimulation of platelets were examined after achieving a 
preconstricted tone with increasing doses of phenylephrine (10-9 to 10-6 mol/L) to obtain a similar 
level of precontraction in each ring (80% of initial KCl-induced contraction). 
 
Measurement of platelet aggregation  
Isolated platelets were centrifuged at 1500 g for 10 minutes and platelets were washed twice with 
a 6:1 mixture of Hank’s balanced salt solution (HBSS) and Acid citrate dextrose (ACD).  
Platelet-rich plasma (PRP) were incubated with 5, 15, 20, 25 or 50 mmol/L glucose or mannitol in 
the presence or absence of NSC23766 (15, 30, 50, 60, 75, 150 and 300 μM), EHT 1864 (Tocris 
Bioscience; 50 and 100 μM) or LY27632 for 30 minutes at 37°C. Platelet aggregation was monitored 
at 37°C with constant stirring (1200 rpm) in a dualchannel lumi-aggregometer (model 700; Chrono-
Log). The maximum aggregation was expressed as a percentage of maximum light transmission, with 
unstimulated PPP being 0% and stimulated PRP 100%.  Platelet aggregation was measured as the 
increase in light transmission for 5 minutes, with the addition of 0.8 μg/ml collagen, arachidonic acid 
(AA: 0.5 mM), adenosine diphosphate (ADP: 50 mM) or thrombin receptor-activating peptide 
(TRAP: 25µM) (Chrono-Log) as a proaggregatory stimuli. 
 
Measurement of nitric oxide production in platelets 
Platelet were resuspended (100 µL) in HBSS at room temperature and stimulated for 10 minutes 
with 1 µmol/L insulin. After incubation, the measurement of nitric oxide in platelets-supernatants 
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Rac1-GTP pull-down experiments.  
Pooled mice mesenteric arteries, HUVECs, and human platelets were isolated as previous 
described. After glucose-exposure (5 or 25 mmol/L) or mannitol (5 or 25 mmol/L) or NSC23766 (30 
µmol/L) or LY27632 (30 µmol/L) at 37°C, tissues or cells were lysed in a buffer containing NP-40 
equipped by kit. In some platelets samples, after pre-incubation with glucose, mannitol, NSC23766 
or LY27632, platelets were stimulated with 1 µg/ml collagen for 5 min. The reaction was terminated 
by the addition of an ice-cold EDTA (10 mmol/L) solution, followed by centrifugation at 10000g at 
4°C for 2 minutes 6. P21-binding domain (PBD) of p21-activated protein kinase (PAK) bound to 
agarose beads was added, and active Rac1, binding PAK1, was separated by repetitive centrifugation 
and washing. After, the specimens were boiled in Laemmli buffer, subjected to SDS-PAGE, and Rac 
was quantified by western blot analysis. In details, Rac1-GTP was detected with the monoclonal 
antibodies anti-Rac1-GTPγ (1:800; STA-401-1, Cells Biolab Inc.), and total Rac1 with monoclonal 
anti-Rac1 (1:1000; Abcam). Densitometry analysis was performed using Quantity One software (Bio-
Rad Laboratories). The amount of Rac1-GTP was normalized to the total amount of Rac1 or GAPDH 
in mesenteric arteries or in cell lysates for the comparison of Rac1 activity (GTP-bound Rac1) among 
different samples.  
 
Platelet fractionation  
Blood was collected from the heart through cardiac puncture of isofluorane-anesthetized mice. 
PRP was prepared by addling 1-2 ml of saline to pooled blood and centrifuging the blood at 150 g for 
10 min at ambient temperature. Platelets were quickly resuspended at 4° C in 1 mL of hypotonic 
buffer (5mM Tris-HCl/5mM EDTA, ph 7.5) and frozen in liquid nitrogen. Five cycles of rapid 
freezing and thawing lysed the cells, and the homogenate was centrifuged at 160000 g for 15 min. 
The resulting supernatant, representing the platelets cytosolic fraction, was rapidly removed and 
stored at -20° C. At this point, the pellets were resuspended in 300 µL of Tris/EDTA buffer, and 50 
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This-HCl, 1 mM EDTA and phenylmethylsulfonyl fluoride (45 µg/mL) in each microcentrifuge 
tubes. After centrifugation at 160000 g for 2 min, the membrane fractions were observed as two faint 
bands at the top of the sucrose layer. Membrane fractions were carefully aspirated and diluted in 
buffer Tris/EDTA. Finally, cytosolic and membrane fractions were use to immunoblotting analyses.   
 
Immunoblotting  
Platelets, pooled vessels or cells were solubilized in lysis buffer containing: 20 mmol/L Tris-HCl, 
150 mmol/L NaCl, 20 mmol/L NaF, 2 mmol/L sodium orthovanadate, 1% Nonidet, 100 µg/ml 
leupeptin, 100 µg/ml aprotinin, and 1 mmol/L phenylmethylsulfonyl fluoride. Then, samples were 
left on ice for 30 minutes and centrifuged at 10621 g for 20 minutes, and the supernatants were used 
to perform immunoblot analysis. Total protein levels were determined using the Bradford method. 
Rac1 activity was determined using a commercially available kit (Cell BioLabs Inc. STA-401-1). 50 
micrograms of proteins were resolved on 12% SDS-PAGE, transferred to a nitrocellulose membrane 
and immunoblotted with anti-Rac1-GTP (1:1000, Cell BioLabs) or with anti-Rac1 (1:1000, Abcam); 
anti-ROCK1 (1:800, Abcam); anti-p-eNOS or anti-eNOS (1:800, Abcam); anti-p-PI3K (1:800, 
Thermo Fisher); anti-PI3K (1:1000, Thermo Fisher); anti-PAK1 (1:800, Thermo Fisher); anti-p-Akt 
(1:800, Santa Cruz); anti-Akt (1:1000, Santa Cruz); anti-RhoA-GTP (NewEast Biosciences); anti-
RhoA (Thermo Fisher) and anti-β-Actin (1:1000, Cell signaling) anti CD62 (1:800, Abcam), anti Na/ 
K-ATPase (1:1000, Cell signaling). HRP-conjugated secondary antibodies were used at 1:3000 
dilution (Bio-Rad Laboratories). Protein bands were detected by ECL Prime (Amersham Biosciences) 
and densitometry analysis was performed using Quantity One software (Bio-Rad Laboratories). 
 
RNA extraction and quantitative real-time PCR  
Total RNA from tissue samples was extracted using TRIzol reagent (Invitrogen). Quantitative real-
time PCR (qRT-PCR) assays were carried out to detect mRNA expression using the PrimeScript RT 
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instructions. The levels of ROCK1 transcript were measured by forward primer: 
TCTCATTTGTGCCTTCCTTAC, and reverse primer: ACTGGTGCTACAGTGTCT. β-Actin was 
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SUPPLEMENTAL FIGURES  
 
Supplemental Figure 1. A) Nitroglycerine-evoked vasorelaxation in pre-constricted mesenteric 
arteries (n=4 for each group) treated with low (Glu 5mM, full circles) and high glucose levels (Glu 






Supplemental Figure 2. A) Representative immunoblot (left) and densitometric analysis (right) of 
p-eNOS, eNOS, ROCK1, Rac1-GTP, Rac1 and β-actin in serum-starved HUVECs treated with 5mM 
or 25mM of glucose, stimulated with acethylcholine. Cells have been treated with NSC23766 alone, 
with LY27632 alone or concomitantly with both compound. The data are presented as mean ±SEM 
from three independent experiments.* p<0.05 vs. all. B) Effects of glucose and Rac1 inhibitor 
treatment on NADPH oxidase activity in HUVECs. Levels of NADPH activity was measured by 









Supplemental Figure 3. A) Quantification of platelets aggregation presented as percentage of light 
transmission of platelets from control subjects treated with increasing concentrations of mannitol. 
Data are expressed as mean ± SEM. n= 4 independent experiments from individual subjects B) 
Quantification of platelets aggregation presented as percentage of light transmission of platelets from 
control subjects treated with manitol plus increasing concentrations of NSC23766. Data are presented 
as mean ± SEM. n= 4 independent experiments from individual subjects C) Representative 
immunoblot of Rac1 and Rac1-GTP levels in platelets from control subjects (CTRL) treated with 
mannitol 5mM and 25 mM plus NSC23766, (D) and relative densitometric analysis. n= 4 independent 











Supplemental Figure 4. Quantification of platelets aggregation presented as percentage of light 
transmission of platelets from control (CTRL) and diabetic (Db) subjects treated with two different 
dose of EHT1864. n= 4 independent experiments from individual subjects. *p<0.05 vs. CTRL 0 
(without EHT1864), #p<0.05 vs. Db 0 (without NSC23766). 
 
 
Supplemental Figure 5. A) Acetylcholine (ACh) vasorelaxation in preconstricted mice mesenteric 
arteries in basal condition (Ctrl, full circle) and after i.p. treatment with Rac1 inhibitor, NSC23766 









Supplemental Figure 6. A) Representative immunoblot (left) anddensitometric analysis (right) of 
Rac1-GTP, total Rac1 and β-Actin levels in mesenteric arteries from streptozotocin-treated mice 
injected i.p. with NSC23766 (5mg/Kg) and evaluated at different timepoints (12,48,96 hours). n= 3 
independent experiments. * p<0.05 vs STZ + NSC23766 (12h); # p<0.05 vs STZ + NSC23766 (48h); 
§ p<0.05 vs STZ + NSC23766 (96h).  
 
 
Supplemental Figure 7. A) Representative immunoblots (left) and densitometric analysis (right) 
showing protein levels of CD62, Na/K ATPase, and β-Actin in subcellular fractions (cytosol and 
membranes) of platelets isolated from STZ- and vehicle- treated mice in presence or absence of 
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SUPPLEMENTAL TABLES  
 
Supplemental Table 1. 
 DIABETICS WITHOUT 
ASA (n=15) 
DIABETICS WITH ASA    
(n=7) 
HbA1c ≥ 10% 4 0 
7%≤HbA1c <10% 7 5 
HbA1c <7%. 4 2 
 
Abbreviations used: ASA= acetylsalicylic acid; HbA1c = glycohemoglobin. 
 
Supplemental Table 2. 
Animal groups [n] Blood glucose [mg/dL] Body weight [grams] 
Control [8] 125 ± 11 27.6 ± 0.9 
STZ [10] 453 ± 18* 24.1 ± 0.5 
STZ + NSC23766 [8] 464 ± 13* 24.3 ± 0.4 
Vehicle [8] 128 ± 9 28.1 ± 0.7 
Vehicle + NSC23766 [8] 122 ± 14 27.8 ± 0.5 
 
Characteristics of diabetic mice used in the study. Abbreviations: [n]=numbers; Mice received 
STZ dissolved in 0.1 M citrate buffer (STZ) or a solution of 0.1 M citrate buffer alone (vehicle). 
Control, untreated mice; STZ, streptozotocin-treated mice; STZ + NSC23766, streptozotocin-treated 
mice plus NSC23766; Vehicle, mice treated with sodium citrate buffer alone; Vehicle + NSC23766, 
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